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Abstract
Background: TNF-α plays a role in angiogenesis and collagen synthesis, both essential in the wound healing
process. There are concerns that pre-operative anti-TNF-α treatment may influence the surgical stress response and
increase the risk of surgical complications. The aim of this study was to describe the surgical stress response in
patients with inflammatory bowel disease (IBD) and to investigate whether the pre-operative administration of anti-
tumor necrosis factor alpha (anti-TNF-α) agents modify the surgical stress response.
Methods: This was a prospective, multi-center cohort pilot study. The primary outcome was the change in
concentration of immunological biomarkers of the surgical stress response (TNF-α, IL-6, and IL-10). Secondary outcome
measures were changes in IL-8, IL-17A, C-reactive protein, white blood cells, cortisol, transferrin, ferritin, and D-Dimer in
addition to 30 days’ post-operative complications and length of post-operative stay in the hospital (LOS).
Results: Forty-six patients with IBD undergoing major abdominal surgery were included, and 18 received anti-TNF- α
treatment pre-operatively. Peak increase of most of the immunological biomarkers occurred 6 hours after surgical
incision. Then the concentration decreased after 24 h followed by a plateau at 48 h. After adjusting for confounders
including detectable blood concentrations, no difference in the concentrations of immunological, endocrinological or
haematological biomarkers of stress was found between anti-TNF-α treated and anti-TNF-α naïve patients. No increase
in post-operative complications or LOS was noticed in patients who received anti-TNF-α treatment.
Conclusions: Anti-TNF-α did not affect surgical stress response in this pilot study. Withdrawal of anti-TNF-α drugs
prior to surgical intervention in IBD patients might not be justified without measurement of drug concentration
and drug antibodies.
Trial registration: Clinicaltrails.gov.: NCT01974869.
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Background
Surgical injury induces a stress response with activation
of endocrine, metabolic, and immunologic mediators
aiming to restore hemostasis and induce tissue repair.
The immunologic and inflammatory response to stress is
regulated by cytokines produced in activated macro-
phages, fibroblasts, endothelial cells, and giant cells. Tis-
sue injury and infection are sensed by a group of protein
receptors called pattern recognition receptors (PRRs)
that can be activated by pathogen-associated molecular
patterns (PAMPs) and damage-associated molecular pat-
terns (DAMPs). A wide range of PRRs have been de-
scribed, including membrane bound Toll-like receptors
(TLRs) and C-type lectin receptors (CLRs), or cytoplas-
mic receptors such as NOD (Nucleotide-binding oligo-
merisation domain)-like receptors (NLR). Following
stimulation of these receptors, multiple downstream
proteins will be activated leading to intracellular signal-
ing pathways that culminate in activation (phosphoryl-
ation) of transcription factors such as NF-kB among
others which in turn drive the production of a large
array of both pro- and anti-inflammatory cytokines and
chemokines [1, 2].
The cytokines of special interest include interleukins
(IL) and tumor necrosis factor-alpha (TNF-α).
Anti-TNF-α agents (biologicals) are antibodies di-
rected against this key cytokine acting in two ways: First,
by scavenging soluble TNF-α, thereby preventing activa-
tion of immune cells via TNF-a-receptors; and second,
by “reverse signaling” acting on membrane bound
TNF-α -receptors on monocytes and T-cells inducing
apoptosis and inhibition of further cytokine release [1].
Besides being an important component of the immune
defense, TNF-α plays a role in angiogenesis [2], collagen
synthesis [3–5] and wound healing. Inhibition of these
pathways may impair wound healing after surgery. Sev-
eral observational retrospective studies have been carried
out to investigate the risk of post-operative complica-
tions in patients with IBD who received pre-operative
anti- tumor necrosis factor-alpha (anti-TNF-α) treat-
ment [6–8]. The results of these studies are conflicting
but a common point is that at least 1/3 of patients re-
ceived anti-TNF-α) treatment [8].
The aim of this study was to describe the surgical
stress response in patients with IBD undergoing surgical
intervention and to investigate whether anti-TNF-α
agents modify the surgical stress response.
Methods
Study design
The null hypothesis was that pre-operative administration
of anti-TNF-α agents within 12 weeks before surgery, have
no significant effect on surgical stress response. To
investigate this; a prospective, non-interventional
multi-center pilot study was designed.
The primary outcome measure was the difference in
the plasma concentrations of the main immunological
biomarkers of surgical stress response (TNF-α, IL-6, and
IL-10) between anti-TNF-α treated patients and
anti-TNF-α naive.
The secondary outcome measures were difference in
the plasma concentrations of other biomarkers of surgi-
cal stress including IL-8, IL-17A, the ratio of TNF-α/
IL-10 and Il-6/IL10, cortisol, transferrin, ferritin, and
D-Dimer in addition to 30-days, post-operative compli-
cations and length of hospital stay (LOS). Overall com-
plication was defined as any deviation from the expected
post-operative recovery. Intra-abdominal septic compli-
cations (IASC) were defined as overt anastomotic leak-
age, intra-abdominal abscess formation or enteric fistula.
Superficial surgical site infection (SSI) was defined as
clinically documented skin infection at the site of sur-
gery with or without positive culture. Grade of complica-
tions were assessed using Clavian-Dindo classification of
surgical complications.
The choice of sampling intervals at six, 24 and 48 h
after surgical incision was based on previous investiga-
tions [9–13]. Biomarkers of surgical stress were selected
according to the existing evidence [2, 5, 9, 11–24].
Inclusion criteria: adult patients with Crohn’s disease
(CD) or ulcerative colitis (UC) who were scheduled to
elective intestinal resection or terminal stoma closure in
three Danish university hospitals during the study period
(March 2014–May 2016). Open as well as laparoscopic
approaches were included.
Exclusion criteria: patients with pre-operative sepsis,
acute intestinal obstruction, patients operated in acute set-
ting (within 48 h of admission) and patients who had loop
ileostomy take down without laparotomy or laparoscopy.
Details of the procedures
Laboratory procedures
Peripheral blood samples were taken before the induction
of anesthesia, and six, 24 and 48 h after surgical incision.
EDTA plasma and serum was separated by centrifugation,
aliquoted and stored at − 80 °C until analysis.
The concentration of anti-TNF-α biological com-
pounds administered pre-operatively (drug concentra-
tion) was measured in peripheral blood at the day of
surgery together with antibodies against the specific
compound (anti-drug antibodies). Details of the method
used explained in the laboratory homepage [25].
Cortisol was measured by ELISA (DRG International,
Inc.; Catalog number: EIA 1887; Marburg, Germany).
IL-6, IL-10, IL-17A, and TNF-α were measured by a hu-
man high sensitive magnetic ProCartaPlex luminex kit
(eBioscience; Catalog number: EPX040–00000-801;
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Vienna, Austria). IL-8 and D-Dimer were measured using
ProCartaPlex Human IL-8 simplex, ProCartaPlex Human
D-Dimer simplex, and Human Basic kit (eBioscience; cata-
log numbers: EPX010–10204-901, EPX010–12149-901,
and EPX010–10420-901; Vienna, Austria). All samples
were measured in duplicates according to the manufac-
tures instructions, using the mean for statistical analyses.
Plasma levels of CRP, transferrin, ferritin and D-dimer
were measured using standard methods by the Depart-
ment of Clinical Biochemistry, Copenhagen University
Hospital, Amager and Hvidovre, Denmark.
Anesthesia, surgery and post-operative care
All the operations took place between 08:00 a.m. -
04.00 p.m. to avoid circadian rhythm as a confounder.
General anesthesia was administered according to the
standard practice of the anesthesia department in the
participating hospitals. All patients received single
prophylactic pre-operative antibiotics at the induction of
anesthesia. The type and dose was determined by local
standard of pre-operative care in the participating hospi-
tals. Laparoscopic surgery and enhanced post-operative
recovery principles were the standard procedures in the
participating centers.
Statistical analysis
Sample size
Reference values for the changes in the biomarkers for
surgical stress in IBD patients were not available at the
time of the study to allow precise sample size calcula-
tions. Chalhoub et al. showed that 28 patients were
needed to demonstrate a significant change in TNF-α
concentration after moderately stressful surgery [26].
Moreover, Dimopoulou et al. [14] found that 40 patients
should be included to detect a significant correlation be-
tween the values in TNF-α concentration and
post-operative complications. Based on these two studies
(non-IBD patients) and a meta-analyses by the authors
[8], this pilot study was a priori designed to recruit at
least 40 patients of whom 1/3 had received anti-TNF-α
treatment prior to surgery keeping in mind that repeated
measures will reduce the expected variations in outcome
Statistical methods
Pre-operative and peri-operative characteristics were
compared between anti-TNF-α treated and anti-TNF-α
naïve patients with chi-squared tests. Median,
inter-quartile range (IQR), minimum and maximum
were used to visualize changes in the concentration of
biomarkers from baseline (before operation) to one of
the post-operative follow-up time-points (six, 24 and
48 h after surgical incision). The difference of the me-
dians of the changes from baseline between anti-TNF-α
treated and anti-TNF-α naïve patients was assessed
using a bootstrap approach in which patients (retaining
the up-to-four-measurements per patient) were sampled
with replacement using 1000 bootstrap replicates. To re-
duce bias from confounding, the calculated medians
were weighted by a propensity score, i.e. the inverse of
the estimated probability of the received anti-TNF-α
regimen conditional on potential confounders. These
probabilities were estimated from a multivariable logistic
regression model included: Harvey-Bradshaw index for
disease severity, nutritional risk screening score, paren-
teral nutrition, previous IBD-related abdominal opera-
tions, steroid stress dose, pre-operative Dexamethasone,
epidural analgesia, access to abdominal cavity (open ver-
sus laparoscopic), type of resection and disease classifi-
cation in case of CD. These were pre-operative factors
that were either significantly different between the two
anti-TNF-α regimens, or deemed important determi-
nants from clinical experience. Propensity scores were
re-calculated within each bootstrap replicate.
A permutation test, in which the four measurements
for each patient were randomly redistributed over the
time points in 1000 replicates to assess the null hypoth-
esis of no development, was used to assess the statistical
significance of the changes in the median concentration
of biomarkers over time.
Logistic regression was used to investigate post-operative
outcome where adjustment for confounding was done by
stepwise backwards elimination, starting with a model in-
cluding all pre- and peri-operative characteristics deemed
clinically and/or statistically significant different between
the two treatment groups. Variables were then removed
one by one until all variables had p < 0.10.
All analyses, except for the bootstrap analyses, were
done using IBM SPSS Statistics for Windows, Version
19.0. Armonk, NY: IBM Corp.2010. The bootstrap analyses
were performed in the R environment for statistical com-
puting version 3.1.2. A significance level of 5% was chosen.
We used non-parametric, robust methods for infer-
ence, i.e. a non-parametric bootstrap on the difference
of propensity score weighted medians. These methods
are described in detail in the statistics section of the
paper. The SAMPLE guidelines were not very applicable
to the inferential methods we used. This has been re-
ferred to in the manuscript.
Results
Patients were identified using outpatient’s clinic records,
operation lists and reports from IBD conferences. All pa-
tients who fulfilled the inclusion criteria accepted to par-
ticipate in the project. One patient was excluded because
blood samples were accidently discarded. This explorative
study succeeded, thus, in recruiting 46 patients, of which
18 had one type or another of anti-TNF-α agent treatment
within 3 months prior to surgery.
El-Hussuna et al. BMC Surgery           (2018) 18:91 Page 3 of 10
Background characteristics
Median age was (42.5, IQR 23) years, 25/46 of the pa-
tients were females (54.3%). Median body mass index
was (23.5, IQR 6.3). In anti-TNF- α group, 4/18 (22.2%)
had one or more co-morbidities compared to 7/28
(31.8%) in anti-TNF-α naïve. No difference in the mean
duration of disease was found between anti-TNF-α
treated patients (7.61 SD ± 7.82) years and anti-TNF-α
naive (10.11 SD ± 9.15). Pre-and intra-operative patients’
characteristics are reported in Table 1.
Anti-TNF-α naïve patients had higher rate of previous
IBD surgeries compared to anti-TNF- α treated patients
(p = 0.003). Anti-TNF-α treated patients were more
likely to receive pre-operative parenteral nutritional sup-
port (p = 0.028). Moreover, anti-TNF-α treated patients
with CD had a longer ileocecal/ileo-colic resected seg-
ment (mean 31.11 SD ± 35.51) cm versus 27.43 SD ±
18.83 p = 0.036) and were more likely to suffer from a
stricturing CD phenotype (10/76.9% versus 8/42.1% p =
0.01). But this did not affect the results in multivariate
analyses. Type of surgical incision and type of bowel re-
sections were similar in the two groups.
In the 18 patients who received anti-TNF-α
pre-operatively, different type of anti-TNF-α drugs were
administered using different doses with wide variations
of the interval from last administered dose to surgery
(Table 2). Thus, 44% of anti-TNF-α treated patients had
undetectable drug concentration in peripheral blood and
only three of these 18 patients had anti-drug antibodies
at the time of surgery.
Pattern of change in surgical stress markers in IBD
Figures 1 & 2 depict the surgical stress response accord-
ing to all 12 inflammatory biomarkers. Peak increase in
TNF-α occurred 6 hours after surgical incision (median
0.596, IQR range 0.679) then the concentration de-
creased after 24 h (median 0.517, IQR range 0.969)
followed by a plateau at 48 h (median 0.446, IQR range
0.655). The same pattern was observed for IL-6, IL-8,
IL-10, IL-17A, IL-6/IL-10 ratio, WBC, D-Dimer, ferritin
and transferrin while CRP peaked at 48 h after surgical
incision. The ratio of TNF- α/IL-10 and cortisol de-
creased at 6 hours then started to increase at 24 h reach-
ing a plateau at 48 h. The stress response over time was
significant in all biomarkers (p < 0.01) except TNF-α,
IL-17A and cortisol.
Difference in surgical stress response between the two
groups
There was a tendency towards a higher concentration in
most of the inflammatory biomarkers in patients treated
with anti-TNF-α agents compared to the anti-TNF-α
naive as shown in Fig. 3. This was more pronounced in
patients with detectable drug concentration and no
anti-drug antibodies. However, the differences were not
statistically significant (Table 3).
Sub-group analyses
Sub-group analyses was done by selecting patients who
underwent laparoscopic ileocecal/ileo-colic resections
(12/46) to obtain a homogenous group of patients with
same type of surgical procedure. Then by comparing
anti-TNF-α treated and anti-TNF-α naïve in this
sub-group showed no significant difference in surgical
stress response (results not shown).
Post-operative outcome
No difference was found in adjusted analyses of overall
complications between the two groups (27.8% versus
28.6%), superficial SSI (7.8% versus 7.1%), IASC (5.6%
versus 7.1%) and re-admission rates (22.2% versus 25%).
Mean LOS was 5.33 (± 2.57) for anti-TNF- α treated ver-
sus (6.25 ± 3.01) in the anti-TNF- α naive group. The dif-
ference was not statistically significant. The time interval
between last dose of anti-TNF- α and the day of surgery
did not affect the rate of complications. Nor did the type
of anti-TNF- α agents used (Table 2).
Discussion
This explorative prospective multi-center pilot study de-
scribed the pattern of surgical stress response in IBD pa-
tients as measured by evidence-based biomarkers of
surgical stress response. The results showed that the ad-
ministration of anti-TNF-α drugs in the pre-operative
period did not have a significant effect on the immuno-
logical, hematological or endocrinological biomarkers of
the surgical stress response. At first glance, this might be
unexpected as the anti-TNF-α are potent drugs that
affect the immune system and thus the inflammatory
phase of wound healing. However, deeper insights reveal
that this is not a stand-alone observation because the ef-
fect of anti-TNF- α drugs on surgical site infection and
anastomotic leak was not significant in two nation-wide
database studies [27, 28] and four experimental studies
in which confounders were well controlled and measure-
ments of effective drug concentration were available
[29–32]. Moreover, Lau et al. showed a correlation be-
tween anti-TNF-α drugs concentration of more than
3 μg/mL and post-operative infectious complication but
no wound healing related complications in CD patients
[33]. The measurement of detectable blood concentra-
tion of anti-TNF-α might explain this because-as shown
in this cohort- not all patients who received anti-TNF-α
had a detectable drug concentration in their blood prior
to surgery and some of them had neutralizing antibodies.
This finding may also explain some of the controversies
seen in observational studies [8].
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However, having undetectable drug concentration do
not rule out that anti-TNF-α drugs had an effect on im-
mune system.
Anti-TNF-α drugs did not reduce the concentration of
TNF-α in our study. A finding that is in line with two
other studies [34, 35], in which serial measurements of
17 serum cytokines were conducted in 37 and 24 pa-
tients respectively. This can be related to a
dose-dependent effect in which the anti-TNF-α drugs re-
duce the concentration of TNF-α in higher doses.
Table 1 Pre-operative and intra-operative patients’ characteristics in 46 IBD patients treated with anti-TNFα compared to anti-TNFα naive
Patients’ characteristics Anti-TNFα treat. 18/46 (39.1%) Anti-TNFα naïve 28/46 (60.9%) Uni-variate
Age (mean ± SD) 38.7 ± 16.36 44.39 ± 12.62 ns
Female 11/18 (61.1%) 14/28 (50%) ns
Body mass index 24.93 (±SD 6.12) 24.7 (±SD 5.37) ns
Type of disease n (%) ns
Crohn’s disease 13/18 (72.2%) 19/28 (67.9%)
Ulcerative colitis 5/18 (27.8%) 9/28 (32.1%)
Smoking n (%) ns
Non-or ex-smoker 14/18 (77.8%) 22/28 (78.6%)
Smoker 4/18 (22.2%) 6/28 (21.4%)
Steroids n (%): 7/18 (38.9%) 9/28 (32.1%) ns
Immuno-modulators n (%): 8/18 (44.4%) 7/28 (25%)
NSAID intake preoperative n (%): 0 1/28 (3.6%) ns
Anti-Coagulant intake n (%): 1/18 (5.6%) 0 ns
Harvey-Bradshaw Index in CD patient more than median (7.5) n (%): 4/18 (36.4%) 8/28 (61.5%) ns
Pre-operative Albumin mmol/l (mean ± SD) 33.22 ± 7.53 36.89 ± 4.36 ns
Pre-operative Haemoglobin mmol/l (mean ± SD) 7.86 ± 0.94 8.09 ± 1.01 ns
Nutritional risk screening score n (%) ns
No risk 6/18 (33.3%) 20/28 (71.4%)
Mild 6/18 (33.3%) 4/28 (14.3%)
Moderate 3/18 (16.75) 2/28 (7.1%)
Sever 3/18 (16.7%) 2/28 (7.1%)
Pre-operative parenteral nutrition n (%): 5/18 (27.8%) 1/28 (3.6%) p = 0.028
Steroid stress dose n (%): 5/18 (27.8%) 0 p = 0.003
Dexamethasone n (%) ns
4 mg 1/18 (5.6%) 1/28 (3.6%)
8 mg 2/18 (11.1) 9/28 (32.1%)
Pre-operative Epidural analgesia n (%): 5/18 (27.8%) 7/28 (25%) ns
Access to abdomen n (%) ns
Laparoscopic 13/18 (72.2%) 17/28 (60.7%)
Converted 3/18 (16.7%) 2/28 (7.1%)
Open 2/18 (11.1%) 9/28 (32.15%)
Type or resection n (%) ns
SM & IC 9/18 (50%) 11/28 (39.3%)
Colectomy and/or Rectal 8/18 (44.4%) 12/28 (42.9%)
Stoma closure 1/18 (5.5%) 5/28 (17.8%)
Post-operative Epidural analgesia n (%): 6/18 (33.3%) 12/28 (42.9%) ns
Post-operative NSAID used n (%): 0 2/28 (7.1%) ns
Post-operative parenteral nutritional support n (%): 5/18 (27.8%) 1/28 (3.6%) p = 0.028
All operations were performed with a specialist surgeon in charge. Anti-TNF-α Anti-tumour necrosis factor drugs, Ns non-significant, SM small bowel, IC Ileo-colic
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Table 2 Type of anti-TNF-α agents, duration of treatment, drug concentration and presence of anti-drug antibodies
Drug 0: drug concentration μg/mL before surgery. Drug 6: drug concentration μg/mL 6 h after surgery. Drug 24: drug concentration μg/mL 24 h after surgery.
Drug 48: drug concentration μg/mL 48 h after surgery
Concentration of 0.65 μg/mL refers to undetectable drug concentrations (gray shadowed). Techniques used to measure Anti-drug antibodies are mentioned in the
website of laboratory (http://www.wieslab.com/diagnostic-services/index.php?langId=1&headId=72&subId=143&pageId=195)
Fig. 1 Surgical stress response in 46 patients with inflammatory bowel disease who underwent surgical interventions as part of disease
treatment. Main immunological biomarkers of stress are shown. The box shows the median and inter-quartile while the numbers above show the
concentrations for outliers
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Fig. 2 Surgical stress response in 46 patients with inflammatory bowel disease who underwent surgical interventions as part of disease
treatment. Immunological, endocrinological and hematological biomarkers of stress are shown. The box shows the median and inter-quartile
while the numbers above show concentrations for the outliers
Fig. 3 Surgical stress response in patients treated with anti-TNF-α agents versus anti-TNF-α naive. The figure shows only the main immunological
biomarkers of stress. The box show the median and inter-quartile while the numbers above show the concentrations for outliers
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Verification of such hypothesis as well as finding the
cut-off concentration are to be investigated in experi-
mental studies and/or in clinical studies where the inter-
val between anti-TNF-α administration and surgery is
not more than few days.
We did not find an association between anti-TNF-α
treatment and post-operative outcomes. This did not ap-
pear to be explained by possible clinically and
intra-operative factors that might influence the stress re-
sponse to surgery or drug concentration and presence of
anti-drug antibodies, as we adjusted for these. However,
this might be due to small sample size [8] or due to a
dose-dependent effect of anti-TNF-α on post-operative
outcome [33].
Limitations of this study include the small sample size
(pilot study) and the lack of measurements of other in-
fluential factors in wound healing, for instance vascular
endothelial growth factor (VEGF), granulocytes-
macrophage colony stimulating factor (GM-CSF) and
transforming growth factor (TGF-β). However, these fac-
tors are regulated by IL-6 [23] and other cytokines mea-
sured in this study. Another limitation might be
heterogeneity of patients’ population (CD and UC) and
surgical procedures. However, sub-group analysis did
not change the results which were in line with a recently
published prospective study where the authors included
only CD patients undergoing ileo-caecal resections [36].
The choice of anesthetic agents was left to the routine
practice in the participating departments. This might be
a limitation in the study as different anesthetic agents
may affect the surgical stress response differently [37].
Conclusion
This pilot study showed no difference in surgical stress
response between anti-TNF-α treated and anti-TNF-α
naïve patients. Withdrawal of anti-TNF-α drugs prior to
surgical intervention in IBD patients might not be justi-
fied without measurement of drug concentration and
drug antibodies. Further large sample prospective studies
are needed.
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Table 3 The effect of anti-TNF-α treatment on surgical stress response
Biomarkers
of stress
Change from baseline to 6 h. Change from baseline to 24 h. Change from baseline to 48 h. Change from 6 to 24 h.
median (95% CI) p median (95% CI) p median (95% CI) p median (95% CI) p
TNF-α −0.25 (− 3.54; 0.24) 0.49 −0.20 (−1.97; 0.23) 0.44 0.00 (− 0.19; 2.42) 0.37 0.00 (0.00; 0.16) 0.04
IL-6 − 360.46 (− 668.19; 37.01) 0.13 − 200.86 (− 498.45; 29.67) 0.11 − 139.98 (− 276.06; 7.68) 0.12 3.87 (− 62.26; 163.41) 0.84
IL-10 − 0.97 (− 2.52; 1.34) 0.40 −1.29 (− 8.00; 0.17) 0.10 −0.03 (− 1.06; 0.64) 0.88 − 0.25 (− 1.08; 1.16) 0.40
IL-8 2.79 (− 12.25; 27.16) 0.56 5.25 (− 8.90; 17.55) 0.44 5.95 (− 6.83; 11.30) 0.48 −1.10 (−9.10; 7.80) 0.76
IL-17A 0.00 (− 0.03; 0.58) 0.08 0.00 (−1.13; 0.08) 0.70 0.00 (0.00; 0.15) 0.02 0.00 (−2.45; 0.10) 0.14
TNF-α/IL-10 ratio −0.02 (− 0.30; 1.36) 0.96 0.03 (− 0.10; 3.10) 0.39 0.03 (− 0.15; 0.87) 0.33 0.02 (− 0.12; 0.08) 0.66
IL-6/IL-10 ratio − 100.15 (− 151.21; 30.79) 0.13 −4.87 (− 145.59; 33.27) 0.59 −72.65 (− 123.24; 6.39) 0.13 18.09 (− 36.61; 63.46) 0.23
WBC −0.09 (− 4.55; 3.66) 0.97 − 0.01 (− 3.95; 6.31) 0.78 0.27 (− 3.80; 5.82) 0.65 0.25 (−2.75; 4.70) 0.23
CRP 0.00 (− 4.14; 4.59) 0.88 −46.90 (− 76.10; 26.30) 0.22 −104.64 (− 179.39; 76.25) 0.39 −8.45 (− 55.20; 27.11) 0.62
Cortisol 23.80 (− 266.92; 110.51) 0.37 32.01 (− 10.86; 118.55) 0.20 −17.41 (− 137.82; 89.21) 0.51 9.04 (− 6.33; 38.60) 0.26
D-Dimer −11.14 (− 110.31; 92.14) 0.68 28.59 (− 122.81; 80.70) 0.84 50.64 (− 126.71; 129.29) 0.61 5.95 (− 39.99; 69.11) 0.57
Ferritin −2.20 (−6.58; 3.50) 0.48 − 0.35 (− 5.08; 3.92) 0.75 −1.33 (− 6.56; 2.98) 0.26 0.60 (− 6.31; 5.60) 0.91
Transferrin −0.02 (− 0.23; 0.21) 0.93 −0.06 (− 0.30; 0.13) 0.4 −0.20 (− 0.40; 0.09) 0.15 0.02 (− 0.14; 0.11) 0.82
Reported in the table are the differences of the medians of the stress markers between anti-TNF-α naive and anti-TNF-α treated patients. Adjustment for
confounding was done by propensity score weighting of the medians. 95% confidence intervals (95%CI) and p-values are estimated using a bootstrap approach
P: refers to p value
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